You are here: Industry Insights > REGEN-COV

News List

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% worldpharmanews
April 14, 2021
Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 ...
Eli Lilly Stops Distribution of Bamlanivimab as COVID-19 Treatment americanpharmaceuticalreview
March 29, 2021
The US government in coordination with Eli Lilly said it will no longer distribute the COVID-19 monoclonal antibody therapy bamlanivimab for use on its own.
REGEN-COV™ antibody cocktail reduces hospitalisation or death by 70 percent europeanpharmaceuticalreview
March 24, 2021
Phase III data shows treatment with REGEN-COV™ (casirivimab and imdevimab) significantly reduces the risk of high-risk COVID-19 infected outpatients being hospitalised or dying.
Panel finds efficacy for Regeneron’s REGEN-COV in Phase III Covid-19 trial pharmaceutical-technology
March 01, 2021
Regeneron Pharmaceuticals has announced that Independent Data Monitoring Committee (IDMC) found its REGEN-COV antibody cocktail to have clear clinical efficacy in cutting down the rates of hospitalisation and deaths in patients in a Phase III Covid-19 ...
Regeneron 4Q and FY20 Results contractpharma
February 07, 2021
REGEN-COV antibody cocktail for COVID-19 received FDA EUA; Net sales of REGEN-COV were $146 million in the quarter and $186 million for the year.
Study finds some antibody therapies are not effective against new COVID-19 variants europeanpharmaceuticalreview
January 29, 2021
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
REGEN-COV prevents symptomatic COVID-19 infections, finds analysis europeanpharmaceuticalreview
January 28, 2021
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.

Previous page 1 2 Next page